Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires robust T-cell expansion and engraftment. A T-cell defect in chronic lymphocytic leukemia (CLL) due to disease and/or therapy impairs ex vivo expansion and response to CAR T cells. To evaluate the effect of ibrutinib treatment on the T-cell compartment in CLL as it relates to CAR T-cell generation, we examined the phenotype and function of T cells in a cohort of CLL patients during their course of treatment with ibrutinib. We found that ≥5 cycles of ibrutinib therapy improved the expansion of CD19-directed CAR T cells (CTL019), in association with decreased expression of the immunosuppressive molecule programmed cell death 1 on T cells and of CD200 on B-CLL cells. In support of these findings, we observed that 3 CLL patients who had been treated with ibrutinib for ≥1 year at the time of T-cell collection had improved ex vivo and in vivo CTL019 expansion, which correlated positively together and with clinical response. Lastly, we show that ibrutinib exposure does not impair CAR T-cell function in vitro but does improve CAR T-cell engraftment, tumor clearance, and survival in human xenograft models of resistant acute lymphocytic leukemia and CLL when administered concurrently. Our collective findings indicate that ibrutinib enhances CAR T-cell function and suggest that clinical trials with combination therapy are warranted. Our studies demonstrate that improved T-cell function may also contribute to the efficacy of ibrutinib in CLL. These trials were registered at www.clinicaltrials.gov as #NCT01747486, #NCT01105247, and #NCT01217749.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, CAR T-cell fitness is related to the quality of the starting T cells obtained by apheresis, which may be affected by tumor and prior therapy.3,39,40”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · cited 1×
“Small-scale ex vivo expansions from peripheral blood samples and clinical-grade expansions of leukapheresis products were performed in the Clinical Cell and Vaccine Production Facility as described.(7) Carboxyfluorescein succinimidyl ester–labeled T cells(21) were incubated with media alone or increasing concentration…”
MethodSelf-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388 · cited 1×
“Quantitative polymerase chain reaction analysis of genomic DNA samples was performed in bulk using 200 ng of genomic DNA per condition, Applied Biosystems TaqMan technology, and a validated assay to detect the integrated anti-CD19 CAR transgene sequence.(8) Each data point (samples, standard curve, reference controls)…”
MethodSelf-citationCTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729 · cited 6×
“To examine the relationship between ex vivo expansion of T cells and efficacy of CTL019 in CLL patients, we compared the proliferative burst of T cells andCTL019 cells in ibrutinib-naı̈veCLLpatients who achieved a CR, a partial response, or no response to CTL019 treatment; the clinical history and outcomes of these pa…”
BackgroundResultInfluentialSelf-citationKochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275 · cited 1×
“For in vitro experiments, we briefly exposed T cells to ibrutinib and then performed a wash to allow only for specific and irreversible binding to ITK, rather than nonspecific kinase inhibition.(17,35,36) Supraphysiological doses of ibrutinib did not impair or enhance transduction with the anti-CD19 CAR lentiviral vec…”
Self-citation
Cited by
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Self-citationEngineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Self-citationTurtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862
Self-citation
Metadata
- Authors
- Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., Zhang, C., Xu, J., Do, P., Hulitt, J., Kudchodkar, S. B., Cogdill, A. P., Gill, S., Porter, D. L., Woyach, J. A., Long, M., Johnson, A. J., Maddocks, K., Muthusamy, N., Levine, B. L., June, C. H., Byrd, J. C., & Maus, M. V.
- Affiliations
- Abramson Cancer Center (US)
- The Ohio State University (US)
- Children's Hospital of Philadelphia (US)
- Center for Cellular Immunotherapies and
- Harvard University (US)
- Corresponding author
- Fraietta, Joseph A.
- Beckwith, Kyle A.
- Byrd, John C.
- Maus, Marcela V.
- ORCID
- Fraietta, Joseph A.
- Beckwith, Kyle A.
- Ruella, Marco
- Zheng, Zhaohui
- Barrett, David M.
- Lacey, Simon F.
- Melenhorst, Jan Joseph
- McGettigan, Shannon E.
- Cook, Danielle R.
- Zhang, Changfeng
- Xu, Jun
- Do, Priscilla
- Kudchodkar, Sagar B.
- Cogdill, Alexandria P.
- Gill, Saar
- Porter, David L.
- Woyach, Jennifer A.
- Long, Meixiao
- Johnson, Amy J.
- Maddocks, Kami
- Muthusamy, Natarajan
- Levine, Bruce L.
- June, Carl H.
- Byrd, John C.
- Maus, Marcela V.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-03-03
- Volume
- 127
- Issue
- 9
- Pages
- 1117-1127
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC4778162
- OpenAlex
- W2296829012
- Cited by
- 474
- References
- 53
- Citations by year
- 2026: 26 · 2025: 26 · 2024: 35 · 2023: 37 · 2022: 59 · 2021: 70 · 2020: 71 · 2019: 56 · 2018: 42 · 2017: 30 · 2016: 21
- FWCI
- 26.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (4p01ca081534-16)
- National Cancer Institute (P01CA095426, T32CA009140, R35 CA198183, R01CA165206, K23CA178183, K08CA166039, P30CA016058, R01CA177292, P30CA016520, P01-CA-081534)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- ibrutinib, CAR T-cell therapy, CD19 CAR T cells, chronic lymphocytic leukemia, acute lymphoblastic leukemia, T cell engraftment, T cell expansion, PD-1, CD200, combination therapy, xenograft models
- MeSH terms
- Adenine, Administration, Oral, Aged, Animals, Cytotoxicity, Immunologic, Demography, Disease Models, Animal, Humans, Immunosuppression Therapy, Male, Middle Aged, Piperidines, Pyrazoles, Pyrimidines, Receptors, Antigen, T-Cell, T-Lymphocytes, Time Factors, Leukemia, Lymphocytic, Chronic, B-Cell, Antigens, CD, Treatment Outcome, Gene Transfer Techniques, Drug Resistance, Neoplasm, K562 Cells, Cell Line, Tumor, Cell Proliferation, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. https://app.cochat.ai/papers/10.1182/blood-2015-11-679134
- The paper
- Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., Zhang, C., Xu, J., Do, P., Hulitt, J., Kudchodkar, S. B., Cogdill, A. P., Gill, S., Porter, D. L., Woyach, J. A., . . . Maus, M. V. (2016). Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. https://doi.org/10.1182/blood-2015-11-679134
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.